Ankyra Therapeutics develops cancer therapies using tumor-localized immune potentiating agents to boost anti-tumor immune responses. The company’s platform forms an extended drug depot after intratumoral administration to expand the therapeutic window of cytokine drugs, prolong immune activation, and reduce systemic toxicity. Its lead molecule, ANK-101, is being progressed through IND enabling studies and into planned Phase 1 clinical trials. Proceeds from the recent Series B will also support advancement of additional cytokine programs. Ankyra appointed Howard L. Kaufman, M.D. as Chief Medical Officer to support clinical development efforts. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Total raised

$45M

Funding rounds

1

Latest round

Series B

Latest activity

Nov 2021